Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is Caligan Partners LP's 9th Largest Position

Caligan Partners LP raised its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 47.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,767,982 shares of the company's stock after acquiring an additional 572,729 shares during the period. Y-mAbs Therapeutics accounts for approximately 3.7% of Caligan Partners LP's portfolio, making the stock its 9th largest position. Caligan Partners LP owned approximately 3.95% of Y-mAbs Therapeutics worth $13,843,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in YMAB. Barclays PLC lifted its stake in shares of Y-mAbs Therapeutics by 433.4% during the third quarter. Barclays PLC now owns 69,222 shares of the company's stock valued at $910,000 after buying an additional 56,244 shares during the period. Geode Capital Management LLC grew its position in shares of Y-mAbs Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock worth $10,699,000 after acquiring an additional 47,846 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics during the third quarter worth about $267,000. JPMorgan Chase & Co. grew its stake in Y-mAbs Therapeutics by 10.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock worth $399,000 after buying an additional 2,854 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

Wall Street Analysts Forecast Growth

YMAB has been the subject of a number of research reports. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a report on Tuesday, April 22nd. Wedbush reaffirmed an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. HC Wainwright decreased their price target on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Finally, Truist Financial dropped their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $17.40.

Y-mAbs Therapeutics Trading Down 6.9 %

YMAB stock traded down $0.30 during mid-day trading on Tuesday, reaching $3.96. The company's stock had a trading volume of 213,267 shares, compared to its average volume of 325,088. The business's 50 day moving average price is $4.68 and its 200 day moving average price is $7.68. Y-mAbs Therapeutics, Inc. has a 12 month low of $3.84 and a 12 month high of $17.47. The company has a market cap of $179.07 million, a price-to-earnings ratio of -7.32 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million during the quarter, compared to analysts' expectations of $26.70 million. During the same period in the prior year, the business earned ($0.02) earnings per share. As a group, equities analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.50% of the stock is owned by insiders.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.